Target Audience
- Researchers and professionals with a foundational understanding of genomics and DNA/RNA sequencing who want to explore how sequencing technologies are being commercialized.
- Scientists, engineers, and industry professionals interested in Oxford Nanopore Technologies (ONT), its technological advantages, competitive landscape, and corporate strategy.
- Readers interested in how advances in genomic analysis may transform clinical diagnostics and biopharmaceutical development.
Executive Summary
- Oxford Nanopore Technologies (ONT) is transitioning from an innovative sequencing technology provider into an industrial platform supporting clinical diagnostics, biopharmaceutical manufacturing, and large-scale genomic analysis.
- ONT's greatest technological strength lies in its ability to directly sequence long DNA and RNA molecules while integrating information about nucleotide sequences, structural variants, haplotypes, and base modifications.
- In 2026, ONT introduced a significant strategic shift, accelerating its expansion beyond research-focused applications into higher-value Clinical and BioPharma markets.
- The company's growth through 2030 will depend not only on sequencing performance but also on clinical utility, adoption in pharmaceutical quality control, recurring consumables revenue, and improved profitability.
- ONT's future will ultimately be determined not by whether it can build a better sequencer than Illumina or PacBio, but by whether it can deliver clinically actionable biological information through a single workflow that previously required multiple separate assays.
1. Oxford Nanopore Technologies Is at a Critical Turning Point
Oxford Nanopore Technologies (ONT), a UK-based sequencing technology company, is entering an important phase of its development.
As of 2026, the company is seeking to evolve from a provider of innovative sequencing technology into an industrial platform supporting clinical diagnostics, biopharmaceutical manufacturing, and large-scale genomic analysis.
For many researchers, ONT is best known for its MinION portable sequencer and its ability to directly sequence long DNA molecules using nanopore technology.
Historically, the company has established a distinctive technological platform that enables real-time DNA and RNA analysis through a fundamentally different sequencing mechanism.
However, understanding ONT's current position requires looking beyond technological advances alone.
The company is moving from a business centered on selling innovative research instruments toward one in which its technology becomes embedded in routine hospital operations and pharmaceutical manufacturing workflows.
Five developments are particularly important in evaluating whether this transition will succeed.
1.1 ONT's Technological Advantages Remain Distinctive and Continue to Expand
ONT can provide ultra-long reads, native DNA/RNA sequencing, direct methylation detection, real-time analysis, and adaptive sampling within a single technology platform.
The ability to combine these capabilities remains one of ONT's most important competitive advantages.
1.2 The Competitive Focus of Long-Read Sequencing Is Changing
Historically, competition in long-read sequencing has focused heavily on read length and sequencing accuracy.
However, future competition will increasingly depend on how much clinically and industrially valuable information can be extracted from sequencing data.
This includes the reliable and cost-effective characterization of structural variants (SVs), repeat expansions, haplotypes, DNA modifications, and transcript isoforms.
1.3 ONT Introduced a Major Strategic Shift in 2026
Under Francis Van Parys, who became CEO in March 2026, ONT has clarified its intention to move from broad, research-oriented technology development toward concentrating resources on higher-value applications in Clinical and BioPharma markets.[1]
1.4 Financial Performance Is Improving, but Challenges Remain
Revenue increased by 10.5% year over year in the first half of 2026, while gross margin improved to 62.2%.
Nevertheless, ONT remains unprofitable.
The company is targeting adjusted EBITDA breakeven in 2027 and positive free cash flow in 2028.[1]
1.5 The Greatest Opportunity Is Integrating Multiple Genomic Assays into a Single Workflow
Some of ONT's most promising growth opportunities lie in molecular cancer classification, rare diseases, infectious diseases, and quality control for cell and gene therapies.
These are areas where ONT may demonstrate value beyond competing directly with short-read sequencing on price.
ONT's future will not be determined simply by whether it develops a better sequencer than Illumina or PacBio. Instead, it will depend on whether the company can transform biological information that currently requires multiple assays into clinically usable results from a single measurement.
The following sections examine ONT's current business position, technological capabilities, competitive landscape, and future growth strategy.
2. Current Business Position: Financial Performance and Market Trends in 2026
2.1 Recent Financial Performance
We begin by examining ONT's financial position.
According to the company's interim financial results published on August 19, 2026, its key metrics for the first half of 2026 were as follows.[1]
| Metric | H1 2026 | Year-over-Year Comparison |
|---|---|---|
| Revenue | £116.7m | +10.5% |
| Gross margin | 62.2% | +4.0 percentage points |
| Adjusted EBITDA | −£22.1m | Improved from −£48.3m |
| Cash and liquid investments | £234.5m | As of June 30, 2026 |
Revenue continues to grow, and profitability metrics have improved significantly.
The adjusted EBITDA loss has narrowed considerably, while gross margin has increased.
However, revenue growth has not accelerated consistently.
Full-year revenue for 2025 was £223.9m, representing growth of 24.2% on a constant-currency basis.[2]
By comparison, constant-currency revenue growth slowed to 12.3% in the first half of 2026.[1]
A comparison of first-half revenue illustrates this trend.
| Period | Revenue |
|---|---|
| H1 2025 | £105.6m |
| H1 2026 | £116.7m |
Several factors contributed to the slowdown, including export restrictions and changes in the commercial environment in China, the completion of major research projects, and regional disruptions.[1]
However, this should not automatically be interpreted as weakening demand for ONT's technology.
Large-scale research projects can cause substantial fluctuations in revenue depending on when projects begin, end, and generate recognized revenue.
Furthermore, the growth dynamics of research markets differ considerably from those of clinical and pharmaceutical markets.
2.2 Growth Is Increasingly Concentrated in Clinical and BioPharma Markets
ONT's revenue growth by customer segment in the first half of 2026 reveals an important pattern.[1]
| Customer Segment | Year-over-Year Revenue Growth |
|---|---|
| Clinical | +35.4% |
| BioPharma | +25.0% |
| Industrial | +6.2% |
| Research | +5.4% |
Research remains ONT's largest market, accounting for approximately 65% of revenue.
However, Clinical and BioPharma are growing much faster.
In the first half of 2026, Clinical represented 15.1% of revenue, while BioPharma accounted for 8.1%.[1]
This represents a strategically important shift.
Selling sequencing instruments to research institutions is fundamentally different from integrating sequencing technologies into pharmaceutical GMP environments or hospital diagnostic workflows.
The latter requires far more than sequencing accuracy.
Critical requirements include:
- Lot-to-lot consistency
- Instrument uptime and reliability
- Sample-to-answer turnaround time
- Software version control
- Analytical validation
- Regulatory compliance
- Data traceability
In other words, developing a technically sophisticated sequencer is no longer sufficient.
ONT must establish its products as reliable systems that can operate consistently within routine clinical and industrial environments.
The company's next phase of growth will depend heavily on how effectively it meets these requirements.
3. Technological Competitiveness: How Far Has ONT Advanced?
3.1 Sequencing Accuracy Can No Longer Be Summarized as "Nanopore Sequencing Has High Error Rates"
Nanopore sequencing works by measuring changes in ionic current as DNA or RNA molecules pass through a protein nanopore.
Machine learning models interpret these electrical signals to infer nucleotide sequences.
This mechanism differs fundamentally from PacBio's single-molecule real-time (SMRT) sequencing and Illumina's sequencing-by-synthesis technology.
ONT provides instruments across a wide range of throughput requirements, from portable MinION devices to high-throughput PromethION systems.
Historically, read-level accuracy was one of the most significant limitations of nanopore sequencing.
However, improvements in R10.4.1 chemistry, motor proteins, and neural-network-based basecalling through Dorado have substantially improved performance.
ONT has reported raw-read accuracy of 99.75% (Q26) using Dorado v5-series models.[3]
Importantly, this figure reflects performance under specific conditions and should not be interpreted as a guarantee across all samples, sequence contexts, or nucleotide modifications.
When evaluating sequencing accuracy, at least four distinct concepts must be considered.
| Accuracy Metric | Meaning |
|---|---|
| Simplex read accuracy | Accuracy inferred from sequencing a single DNA strand |
| Duplex accuracy | Higher-accuracy inference using signals from both strands of the same DNA molecule |
| Consensus accuracy | Accuracy of a consensus sequence constructed from multiple reads |
| Variant calling accuracy | Precision and recall for particular classes of genetic variants |
A particularly important consideration is that Q-scores alone do not establish clinical-grade performance.
Different applications are affected by different error characteristics, including:
- Homopolymer-associated indels
- Low-complexity regions
- Allele balance
- Mosaic variants
- Modification-induced signal shifts
- Reference bias
Consequently, future technological competition will depend not only on improvements in single-read accuracy but also on how consistently ONT can characterize and control errors across different variant classes.
3.2 The Greatest Differentiator Is Native Molecule Sequencing
ONT's most important competitive advantage may not be long-read sequencing itself, but its ability to extract multiple types of biological information from native molecules.
For example, information about the following features can be linked along the same DNA molecule:
- Single-nucleotide variants (SNVs) and small indels
- Structural variants (SVs)
- STRs/VNTRs and repeat expansions
- Haplotype phasing
- DNA modifications, including CpG methylation
This means that sequencing can provide not only nucleotide sequence information but also insights into genomic structure, haplotype origin, and epigenetic state.
Consider the investigation of abnormal gene expression at a particular locus.
Traditionally, researchers might need to analyze promoter methylation, structural variation, and sequence variants using separate methods.
With native long-read sequencing, it becomes possible to determine which haplotype is methylated and whether that same haplotype carries cis-regulatory variants or structural rearrangements.
This capability is particularly valuable for studying:
- Imprinting disorders
- Repeat expansion diseases
- Allele-specific methylation
- Complex structural alterations in cancer
ONT provides models for detecting DNA modifications such as 5mC and 5hmC, as well as several types of RNA modifications.[3]
However, modified-base calling accuracy depends on the modification type, sequence context, and training data used by the underlying machine learning models.
It would therefore be inappropriate to assume uniform detection performance across all modifications.
3.3 ONT's Distinctiveness May Be Even Greater in RNA Sequencing
ONT's direct RNA sequencing technology is particularly interesting because it can sequence RNA molecules without first converting them into cDNA.
This approach provides several potential advantages:
- Analysis of full-length transcripts and isoform structures
- Estimation of poly(A) tail length
- Characterization of RNA modifications
- Avoidance of reverse-transcription and PCR artifacts
- Integration of sequence, modification, and transcript structure at the individual RNA molecule level
For example, researchers may be able to distinguish transcript isoforms from the same gene and investigate how RNA modifications relate to specific isoforms.
However, important technical limitations remain.
These include RNA degradation, input requirements, throughput limitations, 3′-end sequencing bias, and calibration of modification detection models.
In applications such as single-cell transcriptomics, where extremely large numbers of RNA molecules must be analyzed cost-effectively, ONT is unlikely to replace high-throughput short-read methods entirely.
Instead, its strongest opportunities may lie in complementary applications.
For example, short-read RNA-seq can identify a biological phenomenon, while long-read or direct RNA sequencing can provide deeper characterization of full-length transcripts and RNA modifications.
ONT may also find opportunities to integrate these capabilities into specific clinical and manufacturing workflows.
4. How Will ONT Compete with PacBio and Illumina?
Understanding ONT's competitive position requires recognizing that the sequencing market contains several distinct competitive dimensions.
A qualitative comparison of the three major technology platforms is shown below.
| Comparison | ONT | PacBio HiFi | Illumina |
|---|---|---|---|
| Read length | Long to ultra-long | Long, generally on the order of tens of kilobases | Short |
| Single-read accuracy | Improving; context-dependent | Very high | Very high |
| Native methylation analysis | Major strength | Supported, depending on analysis methods | Standard SBS generally requires additional methods |
| Real-time sequencing | Major strength | Limited | Limited |
| Adaptive sampling | Available | No equivalent standard implementation | No equivalent standard implementation |
| Clinical adoption infrastructure | Developing | Developing | Extensive |
| Principal advantages | Integrated information, speed, flexibility | High-accuracy long reads | Maturity, large-scale throughput, ecosystem |
This is a qualitative comparison.
Actual accuracy, cost, and throughput depend on instrument generation, library preparation, analysis pipelines, and the biological application.
4.1 Competition with PacBio: Similar Technological Space, Different Value Propositions
Pacific Biosciences (PacBio) offers HiFi sequencing, which combines high per-read accuracy with long-range genomic information.
When comparing PacBio and ONT, it is insufficient to focus only on F1-scores for SNVs and indels.
For complex genomic regions, performance depends on factors such as:
- Distribution of sequenced molecule lengths
- Haplotype block length
- Ability to resolve structural variant breakpoints
- Mappability in repetitive regions
- Modification detection performance
- Total analytical cost per sample
A benchmark of long-read structural variant callers published in September 2026 also demonstrated that detection performance depends not only on the sequencing platform but also on variant type, analytical algorithms, and sequencing coverage.[4]
Looking ahead, PacBio is likely to continue emphasizing the quality of high-accuracy long reads.
ONT, meanwhile, is likely to differentiate itself through the integration of read length, speed, modification information, and flexible throughput.
Although the companies compete directly in many applications, their technologies are not necessarily interchangeable across all use cases.
4.2 Competition with Illumina: Redefining Diagnostic Value Rather Than Replacing Short Reads Entirely
Illumina has established an extensive ecosystem of instruments, reagents, analytical software, and clinical infrastructure around short-read sequencing.
Short-read sequencing is likely to remain highly competitive in applications such as:
- Routine whole-genome sequencing
- Targeted oncology panels
- High-throughput RNA sequencing
ONT's strongest opportunities may arise where it can consolidate multiple existing tests into a single workflow.
Consider comprehensive genomic testing for a particular disease.
Conventional testing workflow
Short-read WGS + methylation array + repeat expansion assay + additional structural variant testing
Potential ONT-based workflow
Native long-read WGS + integrated variant and modification analysis
If this integration reduces the number of additional tests, improves diagnostic yield, and accelerates clinical decision-making, ONT may be adopted even when sequencing cost per gigabase is somewhat higher.
In other words, the unit of competition changes.
Historically, one of the primary metrics has been cost per Gb.
In clinical applications, however, cost per clinically actionable answer may become more important.
This represents the total cost required to obtain information that can meaningfully inform clinical decisions.
Nevertheless, such integration will not be possible for every disease or diagnostic application.
Prospective validation of diagnostic sensitivity, reproducibility, and economic value will be essential.
5. Four Areas Likely to Drive Future Growth
Four areas are particularly important when considering ONT's future:
- Clinical Genomics
- BioPharma Quality Control
- Population-scale Genomics
- Molecular Sensing
These opportunities differ substantially in their commercialization timelines and technological maturity requirements.
5.1 Clinical Genomics: Potentially the Largest Strategic Opportunity
Among clinical applications, methylation-based brain tumor classification is a particularly important example for evaluating ONT's future.
On September 25, 2026, the UK's National Health Service (NHS) announced a large-scale pilot of rapid genomic testing for brain tumors using ONT technology.[5]
The initiative aims to provide classification results within two hours during surgery for certain cases.
The significance of this application extends beyond sequencing speed.
Molecular classification of brain tumors benefits from several types of genomic information, including:
- DNA methylation profiles
- Copy-number variation (CNV)
- Driver mutations
ONT can use nucleotide sequence and methylation signals from native DNA to perform tumor classification in real time.
In this context, Q-score alone is not the most important performance metric.
More relevant measures include:
- Minimum coverage required for classification
- Classification confidence and assay failure rate
- Proportion of cases receiving results during surgery
- Classification performance for rare tumor subtypes
- Interpretation of agreement and disagreement with pathological diagnoses
- Effects on patient management and treatment decisions
If clinical utility is established, ONT could evolve from a sequencing instrument provider into a real-time molecular pathology platform.
Similar approaches could be extended to acute leukemia, rare diseases, and infectious diseases.
In rare disease genomics, for example, patients whose conditions remain unresolved after short-read WGS may benefit from integrated analysis of repeat expansions, complex SVs, deep intronic rearrangements, and allele-specific methylation.
ONT has also announced initiatives in 2026 involving the MyOme/Natera rare disease analysis platform and participation in Genetic Alliance's RISE program.[1]
However, the pace of clinical adoption will depend on more than technological performance.
Key barriers include reimbursement, clinical evidence, integration with existing diagnostic workflows, and laboratory accreditation.
5.2 BioPharma: A Particularly Attractive Medium-Term Market
Although BioPharma currently accounts for less than 10% of ONT's revenue, it is an attractive market from a business-model perspective.
Unlike one-time research instrument purchases, integration into pharmaceutical manufacturing workflows can generate recurring demand for consumables.
Three applications are particularly relevant.
Quality Control for mRNA Therapeutics
ONT could support integrated characterization of RNA identity, integrity, poly(A) tails, sequence variants, and modification information where technically feasible.
The objective would be to simplify testing workflows that currently require multiple analytical methods.
Quality Control for Cell and Gene Therapies
Long-read sequencing can be used to assess vector integrity, on-target and off-target rearrangements, transgene structure, and complex genome editing outcomes.
Biomanufacturing Process Control
Potential applications include verifying plasmid identity, construct integrity, and genomic stability of engineered cell lines.
An important example is the GMP-oriented direct RNA quality control solution announced with Lonza in May 2026.[6]
This initiative seeks to integrate the evaluation of critical quality attributes of mRNA into a sequencing-based workflow, potentially reducing the time required for testing.
The commercial opportunity is significant.
Once pharmaceutical companies adopt ONT as part of a validated manufacturing QC method, the value proposition extends beyond instrument pricing.
Reliable reagent supply, reproducibility, change management, and regulatory documentation become increasingly important.
However, integration into manufacturing processes requires rigorous method validation.
ONT must therefore mature from a technology that performs well in research settings into one that can be consistently maintained and controlled over long periods.
5.3 Population-scale Genomics: The Strategic Importance of PromethION
ONT's expansion into large-scale cohort sequencing is another important development.
According to its first-half 2026 results, more than 15,000 samples had been processed in connection with UK Biobank activities, with throughput exceeding 400 genomes per week.[1]
In large-scale long-read genomics, the maximum theoretical output of a sequencing instrument is only one component of overall performance.
Total costs are influenced by:
- DNA molecule length and quality after extraction
- Automation of library preparation
- Variability in flow cell yield
- Sequencing throughput and instrument utilization
- Required sequencing coverage
- Computational costs of basecalling and variant calling
- Flow cell reuse and manufacturing yield
At London Calling in May 2026, ONT introduced the PromethION Plus flow cell, highlighting the potential to increase yield without additional washing or reloading.[7]
Such improvements could enhance the economics of large-scale genomic analysis.
However, substantial datasets and standardized analytical frameworks have already been established using short-read WGS in large population cohorts.
Therefore, whether long-read WGS becomes essential for all population-scale sequencing will depend on the population genetic and medical value of additional variants and epigenomic features that it can detect.
In the near term, a more realistic scenario may be the use of long-read WGS in selected, strategically important subsets of large cohorts.
This could help improve pangenome references, structural variant catalogs, repeat variation datasets, and haplotype resolution.
5.4 Protein Sensing: Significant Long-Term Potential, but a Different Investment Horizon
ONT also presented demonstrations of nanopore-based peptide sequencing and amino-acid calling in its 2026 technology updates.[7]
If these capabilities mature sufficiently, they could support a broader vision in which nanopore technologies analyze DNA, RNA, and proteins.
However, it would be premature to assume that protein sequencing will become a major revenue contributor before 2030.
Compared with DNA and RNA sequencing, protein sequencing presents substantial technical challenges.
These include:
- Distinguishing the 20 standard amino acids
- Controlling molecular translocation
- Accommodating differences in peptide length and terminal chemistry
- Detecting post-translational modifications (PTMs)
- Achieving the dynamic range and throughput required for proteome-wide analysis
Protein sensing should therefore be considered a long-term technological opportunity rather than a central component of ONT's current business strategy.
6. Interpreting ONT's Strategic Shift in 2026
Francis Van Parys, who became CEO in March 2026, outlined four strategic priorities in the company's August financial results.[1]
| Strategic Priority | Practical Implication |
|---|---|
| Customer-centric growth | Focus on Clinical and BioPharma applications where ONT can compete effectively |
| Focused innovation | Connect technology development more directly to customer needs and revenue opportunities |
| Disciplined execution | Optimize product portfolios, manufacturing quality, costs, and operations |
| High-performance culture | Strengthen organizational capabilities, including regulatory and GMP execution |
The most important implication is a transition from a technology-driven product roadmap toward an application-driven product roadmap.
Historically, ONT has maintained its competitive position by continuously introducing improvements in chemistry, basecalling, flow cells, and sequencing instruments.
In research markets, the pace of technological innovation is itself a major source of value.
However, frequent technological changes are not necessarily desirable in clinical or pharmaceutical markets.
For example, changing a basecalling model used in GMP quality control may require impact assessments and potentially renewed validation.
Consequently, ONT may increasingly need a two-tier product strategy.
On one hand, research platforms can continue to evolve rapidly.
On the other, products intended for regulated environments must offer stable generations and carefully controlled update cycles.
Products such as GridION Q and GridION Dx are consistent with this direction.
GridION Dx has obtained CE/UKCA marking in the UK and European markets.[8]
However, regulatory progress at the instrument level should not be confused with approval of every diagnostic assay that might use an ONT platform.
ONT also announced a cross-licensing agreement with an undisclosed global diagnostics company in August 2026.[1]
The agreement includes:
- $20 million in licensing revenue
- $15 million in product purchase commitments for 2027–2028
- Royalties linked to sales of covered products
This is strategically interesting because it suggests that ONT may increasingly commercialize its intellectual property through third-party diagnostic products, rather than relying exclusively on direct sequencer sales.
7. Financial Targets Through 2030 and Their Feasibility
In August 2026, ONT announced updated financial objectives extending through 2030.[1]
| Year | Company Target |
|---|---|
| 2027 | Adjusted EBITDA breakeven |
| 2028 | Positive free cash flow (FCF) |
| 2030 | Revenue exceeding $700 million |
| 2030 | Adjusted EBITDA margin above 15% |
These figures represent management targets rather than guaranteed outcomes.
For 2026, ONT forecasts revenue growth of 16–20% on a constant-currency basis.[1]
Importantly, this guidance excludes $20 million in one-time licensing revenue.
Including this licensing revenue, reported growth is expected to be approximately 23–27%.
This distinction is critical.
One-time licensing income can improve reported revenue and gross margin, but it does not necessarily indicate an equivalent improvement in the sustainable growth or profitability of the sequencing business.
7.1 Key Metric 1: Recurring Flow Cell Consumption
More important than the number of sequencing instruments sold is how frequently existing customers continue to use flow cells.
ONT's business model generates recurring revenue when customers repeatedly purchase flow cells and reagents after installing instruments.
An important indicator of commercial maturity will therefore be the growth of stable consumables demand from routine testing, rather than dependence on major research projects.
7.2 Key Metric 2: Improving Gross Margins
ONT's gross margin improved to 62.2% in the first half of 2026.
The company reported consumables gross margin of approximately 75%, compared with approximately 34% for instruments and services.[1]
Further improvements in manufacturing yield, flow cell recovery and reuse, and product mix could create additional opportunities for profitability improvement.
7.3 Key Metric 3: Revenue Contribution from Clinical and BioPharma
Research markets will remain important to ONT.
However, increased recurring utilization in clinical testing and pharmaceutical manufacturing could reduce the company's relative dependence on research funding cycles and large grant-supported projects.
Nevertheless, adoption in regulated markets typically takes time.
It would also be incorrect to assume that an initial adoption automatically guarantees stable revenue.
ONT will continue to face scrutiny regarding cost-effectiveness, competitive alternatives, and supply reliability.
8. Three Scenarios for 2027–2030
The following scenarios represent a technology- and business-oriented assessment rather than ONT's official financial forecasts.
8.1 Bull Case: Successful Standardization of Clinical and Pharmaceutical Workflows
In this scenario, routine demand develops across applications such as brain tumor classification, rare disease diagnostics, infectious disease testing, and mRNA quality control.
Clinical and BioPharma growth accelerates, allowing ONT to convert its strong consumables gross margins into sustainable profitability.
Leading indicators would include:
- Routine adoption across multiple healthcare institutions
- Expansion of validated GMP/QC workflows
- Sustained growth in flow cell utilization
8.2 Base Case: Gradual Expansion While Maintaining the Research Business
In this scenario, Clinical and BioPharma maintain relatively high growth rates, but adoption progresses gradually because of validation requirements, reimbursement considerations, and purchasing cycles.
Research and high-value applied markets coexist, while profitability improves incrementally.
Important indicators would include:
- Clinical adoption in selected applications
- Stable growth in the research business
- Gradual improvements in profitability
8.3 Bear Case: Strong Technology but Insufficient Commercialization
In this scenario, progress in accuracy standardization, quality systems, or cost reduction fails to keep pace with market requirements.
Clinical applications remain largely at the demonstration or pilot stage.
At the same time, reductions in research funding and the completion of major research programs could place pressure on financial performance.
Warning indicators would include:
- Limited conversion from pilot programs to routine testing
- Slowing Clinical and BioPharma revenue growth
- Prolonged cash consumption
8.4 The Base Case Appears Most Plausible at Present
At this stage, the base case appears to be the most reasonable central scenario.
Research and proof-of-concept studies supporting the utility of ONT technology continue to accumulate.
However, adoption in clinical diagnostics and pharmaceutical quality control generally takes longer than the deployment of research instruments.
Financial constraints also remain relevant.
ONT's cash and liquid investments declined from £302.8m at the end of 2025 to £234.5m at the end of June 2026.[1]
If improvements in profitability do not continue, financial constraints could become a more significant factor in the company's strategy.
9. What Should Genomics Professionals Monitor Going Forward?
Rather than evaluating ONT purely as a sequencing instrument manufacturer, it is more useful to monitor how effectively its technology is becoming suitable for real-world applications.
Several research and technical metrics deserve particular attention.
| Area | Important Metrics |
|---|---|
| Human WGS | Stratified benchmarks for SNVs, indels, SVs, and STRs using reference samples such as HG002 |
| Epigenomics | Accuracy, calibration, and haplotype resolution of 5mC/5hmC calling |
| RNA | Full-length transcript recovery and validated performance of RNA modification detection |
| Clinical | Diagnostic yield, turnaround time, failure rate, and clinical utility |
| BioPharma | GMP validation, lot-to-lot reproducibility, and replacement of existing QC assays |
| Economics | Cost per reportable genome, flow cell utilization, and recurring revenue |
| Software | Reproducibility across basecaller updates, workflow version control, and auditability |
When evaluating performance, it is especially important to make comparisons using the same samples, equivalent coverage, and the same clinical requirements, rather than focusing on the highest performance figures reported for a single platform.
For example, a very high SNV F1-score may have limited relevance if the clinical application primarily targets specific repeat expansions, complex rearrangements, or low-frequency mosaic variants.
Performance must be evaluated for the variant classes that matter in the intended application.
Similarly, even if a methylation classifier achieves excellent overall accuracy, its behavior must be examined in low-tumor-purity samples and tumor subtypes absent from the reference database.
As ONT technology matures, the distinction between best-case demonstrations and reproducible performance in routine testing will become increasingly important.
10. Overall Assessment: What Does the Future Hold for ONT?
ONT's current position can be evaluated qualitatively across five dimensions.
| Evaluation Area | Score (Out of 5) |
|---|---|
| Technological differentiation | 5 |
| Position in research markets | 4 |
| Clinical commercialization | 2 |
| Future potential in pharmaceutical QC | 4 |
| Financial and operational stability | 3 |
A score of 5 indicates a very strong position, while 1 indicates a weak position.
These are qualitative assessments by the author, not ratings issued by an external organization. Current commercialization progress and future potential are evaluated separately.
From a scientific and technological perspective, ONT's outlook is highly promising.
However, greater caution is warranted when evaluating its financial performance and business growth.
Over the next three to five years, the most likely development is not the wholesale replacement of short-read sequencing by long-read technologies.
Instead, applications that integrate multiple classes of genomic information through native long-read sequencing are likely to become progressively more standardized.
Three areas will be particularly important.
10.1 Clinical Molecular Classification
This includes obtaining faster and more comprehensive diagnostic information in cancer, rare diseases, and infectious diseases.
The key will not simply be sequencing speed, but whether nucleotide sequences, methylation patterns, and other molecular features can be integrated into clinically meaningful decisions.
10.2 Biopharmaceutical Quality Control
This includes integrated characterization of RNA products and complex gene therapy products.
In this market, reproducibility, standardization, and regulatory compliance will be just as important as technological performance.
10.3 Comprehensive Genome Analysis
This involves integrating structural variants, repeats, haplotypes, DNA modifications, and other genomic features into a unified analytical workflow.
The key question is whether obtaining more comprehensive information through a single assay can increase the overall value of genomic analysis.
10.4 Final Perspective
ONT has the technological potential to become a central platform in these areas.
However, there is a substantial gap between demonstrating that a technology is scientifically feasible and establishing it as a clinical or industrial standard.
For a technology that performs well in research to become routinely used in healthcare or pharmaceutical manufacturing, it must satisfy requirements extending far beyond analytical accuracy.
These include quality assurance, cost-effectiveness, regulatory compliance, operational reliability, and integration into established workflows.
ONT's current strategic transformation can be understood as an effort to close this gap.
The period from 2026 to 2030 will likely determine whether ONT can successfully transform its innovative research sequencing technology into an industrial platform supporting clinical diagnostics, biopharmaceutical manufacturing, and large-scale genomic analysis.
References
[1] Oxford Nanopore Technologies, “Interim Results for the 6 Months Ended 30 June 2026,” 2026. https://www.investegate.co.uk/announcement/rns/oxford-nanopore-technologies--ont/interim-results-for-the-6-months-ended-30-june-26/9728523
[2] Oxford Nanopore Technologies, “Annual Report 2025,” 2026. https://nanoporetech.com/api/assets/f/196663/x/e6a62a9b49/ont-ar25-interactive-final.pdf
[3] Oxford Nanopore Technologies, Technical documentation concerning Dorado basecalling and modified-base detection. https://nanoporetech.com/
[4] Comparative benchmarking study of long-read structural variant callers, published September 2026. Note: This study was referenced in the original analysis, but its authors, exact title, and DOI have not been independently identified and should be verified before publication.
[5] NHS East Genomics, “NHS Pilots Rapid Genomic Test to Transform Brain Tumour Diagnosis,” 2026. https://www.eastgenomics.nhs.uk/news-and-events/nhs-pilots-rapid-genomic-test-to-transform-brain-tumour-diagnosis/
[6] Lonza and Oxford Nanopore Technologies, “Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control,” 2026. https://oxfordnanoporedx.com/news/lonza-and-oxford-nanopore-technologies-launch-direct-rna-sequencing-solution-for-gmp-mrna-quality-control
[7] Oxford Nanopore Technologies, “London Calling Technology Update,” 2026. https://nanoporetech.com/news/london-calling-technology-update
[8] Oxford Nanopore Diagnostics, Product and regulatory information concerning GridION Dx and CE/UKCA marking. https://oxfordnanoporedx.com/